ATE525082T1 - Compstatin-analoga mit verbesserter wirkung - Google Patents

Compstatin-analoga mit verbesserter wirkung

Info

Publication number: ATE525082T1
Authority: AT; Austria
Prior art keywords: compounds; improved effects; peptides; disclosed; compstatin analogues
Prior art date: 2002-09-20

Application number

AT03759343T

Other languages

English (en)

Inventor

John Lambris

Original Assignee

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-20

Filing date

2003-09-22

Publication date

2011-10-15

2003-09-22 Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE525082T1 publication Critical patent/ATE525082T1/de

Links

230000000694 effects Effects 0.000 title abstract 2
RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
101710131943 40S ribosomal protein S3a Proteins 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000024203 complement activation Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000816 peptidomimetic Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT03759343T 2002-09-20 2003-09-22 Compstatin-analoga mit verbesserter wirkung ATE525082T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41222002P	2002-09-20	2002-09-20
PCT/US2003/029653 WO2004026328A1 (en)	2002-09-20	2003-09-22	Compstatin analogs with improved activity

Publications (1)

Publication Number	Publication Date
ATE525082T1 true ATE525082T1 (de)	2011-10-15

Family

ID=32030834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03759343T ATE525082T1 (de)	2002-09-20	2003-09-22	Compstatin-analoga mit verbesserter wirkung

Country Status (12)

Country	Link
US (4)	US7989589B2 (de)
EP (3)	EP1549333B1 (de)
JP (3)	JP4614222B2 (de)
AT (1)	ATE525082T1 (de)
AU (1)	AU2003275075A1 (de)
CA (2)	CA2833202C (de)
CY (1)	CY1112198T1 (de)
DK (1)	DK1549333T3 (de)
ES (1)	ES2373649T3 (de)
PT (1)	PT1549333E (de)
SI (1)	SI1549333T1 (de)
WO (1)	WO2004026328A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1549333E (pt) *	2002-09-20	2012-01-03	Univ Pennsylvania	Análogos de compstatina com actividade melhorada
WO2005118020A1 (en) *	2004-04-21	2005-12-15	Allvivo, Inc.	Surface coating comprising bioactive compound
US8168584B2 (en) *	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2662089A3 (de) *	2005-10-08	2014-02-19	Potentia Pharmaceuticals, Inc.	Compstatin und Analoga davon für Augenerkrankungen
CN102977191B (zh) *	2005-11-28	2016-08-10	宾夕法尼亚州大学理事会	有效的c3补体抑制素类似物
AU2013200981B2 (en) *	2005-11-28	2016-01-14	The Trustees Of The University Of Pennsylvania	Potent compstatin analogs
HUE026001T2 (en)	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
WO2008153963A1 (en)	2007-06-08	2008-12-18	The Trustees Of The University Of Pennsylvania	Structure of compstatin-c3 complex and use for rational drug design
WO2009005651A2 (en)	2007-06-29	2009-01-08	The Trustees Of The University Of Pennsylvania	Complement-mediated thrombophilic assay
WO2009015087A2 (en) *	2007-07-20	2009-01-29	Potentia Pharmaceuticals, Inc.	Compositions and methods for treatment of trauma
BRPI0817524A2 (pt) *	2007-10-02	2017-05-02	Potentia Pharmaceuticals Inc	liberação prolongada de análogos de compstatina provenientes de géis
AU2009215846B2 (en)	2008-02-19	2014-08-14	The Trustees Of The University Of Pennsylvania	Complement inhibitors as therapeutic agents for treatment of cancer
US20110190221A1 (en) *	2008-03-28	2011-08-04	Apellis Ag	Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009283889A1 (en)	2008-08-20	2010-02-25	The Trustees Of Columbia University In The City Of New York	Complement inhibitors for treatment of injury from intracerebral hemorrhage
EP2340028B1 (de)	2008-09-30	2018-06-27	The Trustees Of The University Of Pennsylvania	Verfahren zur unterdrückung von biomaterial-induzierter koagulationsfördernder aktivität mit komplement-inhibitoren
CA2760839C (en) *	2009-05-01	2019-02-12	The Trustees Of The University Of Pennsylvania	Modified compstatin with peptide backbone and c-terminal modifications
WO2010135717A2 (en)	2009-05-21	2010-11-25	Potentia Pharmaceuticals, Inc.	Complement assays and uses thereof
WO2011053774A1 (en)	2009-10-30	2011-05-05	Alcon Research, Ltd.	Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9358266B2 (en)	2010-02-25	2016-06-07	The Trustees Of The University Of Pennsylvania	Treatment of sepsis using complement inhibitors
WO2011163394A2 (en)	2010-06-22	2011-12-29	Apellis Pharmaceuticals, Inc.	Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en)	2010-09-23	2012-03-29	The Trustees Of The University Of Pennsylvania	Modified compstatin with improved stability and binding properties
WO2012095519A1 (en)	2011-01-13	2012-07-19	Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie	Potent inhibitors of complement activation
WO2012135624A1 (en)	2011-04-01	2012-10-04	The Trustees Of The University Of Pennsylvania	Treatment of colon cancer using complement inhibitors
MX356528B (es)	2011-05-11	2018-06-01	Apellis Pharmaceuticals Inc	Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
WO2012162215A1 (en)	2011-05-20	2012-11-29	The Trustees Of The University Of Pennsylvania	Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en)	2011-06-13	2012-12-20	The Trustees Of The University Of Pennsylvania	Wound healing using complement inhibitors
EP3524258B1 (de)	2011-06-22	2025-10-01	Apellis Pharmaceuticals, Inc.	Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren
CA2847862C (en)	2011-09-07	2021-01-12	The Trustees Of The University Of Pennsylvania	Compstatin analogs with improved pharmacokinetic properties
MX366404B (es)	2012-11-15	2019-07-08	Apellis Pharmaceuticals Inc	Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014078734A2 (en) *	2012-11-15	2014-05-22	Apellis Pharmaceuticals, Inc.	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
SG10201804960RA (en)	2013-12-12	2018-07-30	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
US10238700B2 (en)	2014-01-02	2019-03-26	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10213476B2 (en)	2014-03-17	2019-02-26	The Trustees Of The University Of Pennsylvania	Compstatin analogs with improved potency and pharmacokinetic properties
CN107148425B (zh) *	2014-10-29	2021-08-03	拜斯科阿迪有限公司	对mt1-mmp特异性的双环肽配体
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US11903994B2 (en)	2015-10-07	2024-02-20	Apellis Pharmaceuticals, Inc.	Dosing regimens
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh)	2017-03-01	2019-12-20	艾其林医药公司	用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
IL269844B2 (en)	2017-04-07	2025-01-01	Apellis Pharmaceuticals Inc	Dosage regimens and related compositions and methods
EP3661493A4 (de)	2017-08-02	2021-04-14	Achillion Pharmaceuticals, Inc.	Therapiepläne zur behandlung von paroxysmaler nächtlicher hämoglobinurie
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
WO2019118938A1 (en)	2017-12-15	2019-06-20	Apellis Pharmaceuticals, Inc.	Dosing regimens and related compositions and methods
RU2020128624A (ru)	2018-02-27	2022-03-28	Зп Спв 3 К/С	Аналоги компстатина и их медицинское применение
EP4011905A3 (de)	2018-04-06	2022-06-29	The Trustees Of The University Of Pennsylvania	Compstatinanaloga mit erhöhter löslichkeit und verbesserten pharmakokinetischen eigenschaften
WO2020051538A1 (en)	2018-09-06	2020-03-12	Achillion Pharmaceuticals, Inc.	Morphic forms of complement factor d inhibitors
JP7443375B2 (ja)	2018-09-06	2024-03-05	アキリオンファーマシューティカルズ，インコーポレーテッド	医学的障害の治療のための大環状化合物
KR20210093855A (ko)	2018-09-25	2021-07-28	아칠리온 파르마세우티칼스 인코포레이티드	보체 인자 d 억제제의 형태체 형태
WO2020131974A1 (en)	2018-12-17	2020-06-25	Achillion Pharmaceuticals, Inc.	Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt)	2019-03-22	2021-11-23	Achillion Pharmaceuticals Inc	Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
BR112022003760A2 (pt)	2019-08-27	2022-05-31	Zp Spv 3 K/S	Análogos de compstatina e seus usos médicos
WO2021081026A1 (en)	2019-10-22	2021-04-29	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
CN115362162A (zh)	2020-02-20	2022-11-18	艾其林医药公司	用于治疗补体因子d介导的障碍的杂芳基化合物
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
JP2023523790A (ja)	2020-04-30	2023-06-07	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
US20230172930A1 (en)	2020-05-12	2023-06-08	Alexion Pharmaceuticals, Inc.	Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
IL299870A (en)	2020-07-16	2023-03-01	Zp Spv 3 K/S	Complement factor C3 inhibitors and their medical uses
CN116437913A (zh)	2020-09-23	2023-07-14	艾其林医药公司	用于治疗补体介导的病症的药物化合物
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
CN118302525A (zh)	2021-10-29	2024-07-05	阿尔尼拉姆医药品有限公司	补体因子B（CFB）iRNA组合物及其使用方法
WO2025176843A1 (en)	2024-02-21	2025-08-28	Ags Therapeutics Sas	Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2026083442A1 (en)	2024-10-15	2026-04-23	Mylan Laboratories Limited	Process for the preparation of pegcetacoplan and its purification using chromatography

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2295746A1 (fr)	1974-12-23	1976-07-23	Francaise Coop Pharma	Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it)	1984-12-12	1987-09-16	Rotta Research Lab	Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en)	1985-04-22	1986-03-18	Merck & Co., Inc.	Tryptophan derivative
US4807097A (en) *	1986-05-14	1989-02-21	Gammache Richard J	Miniature flashlight
US5256642A (en)	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en)	1988-08-03	1992-12-01	New England Deaconess Hospital Corporation	Hirudin-coated biocompatible substance
WO1991016345A1 (en)	1990-04-23	1991-10-31	Rijksuniversiteit Te Utrecht	Cyclic peptides and their use
CA2184356A1 (en)	1994-03-03	1995-09-08	Russell P. Rother	Terminal complement inhibitor fusion genes and proteins
US5776970A (en)	1994-04-28	1998-07-07	Yeda Research And Development Co. Ltd.	Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
US6319897B1 (en) *	1996-03-13	2001-11-20	John D. Lambris	Peptides which inhibit complement activation
US6221621B1 (en)	1997-03-06	2001-04-24	Bard Diagnostic Sciences, Inc.	Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en)	1997-09-04	2001-01-02	The Regents Of The University Of California	Use of tryptophan and analogs as plant growth regulators
WO1999013899A1 (en) *	1997-09-17	1999-03-25	Trustees Of The University Of Pennsylvania	Peptides and peptidomimetics for inhibiting complement activation
AU3485999A (en)	1998-04-10	1999-11-01	Mayo Foundation For Medical Education And Research	Neo-tryptophan
PT1549333E (pt) *	2002-09-20	2012-01-03	Univ Pennsylvania	Análogos de compstatina com actividade melhorada
CN102977191B (zh) *	2005-11-28	2016-08-10	宾夕法尼亚州大学理事会	有效的c3补体抑制素类似物

2003
- 2003-09-22 PT PT03759343T patent/PT1549333E/pt unknown
- 2003-09-22 DK DK03759343.1T patent/DK1549333T3/da active
- 2003-09-22 ES ES03759343T patent/ES2373649T3/es not_active Expired - Lifetime
- 2003-09-22 CA CA2833202A patent/CA2833202C/en not_active Expired - Lifetime
- 2003-09-22 EP EP03759343A patent/EP1549333B1/de not_active Expired - Lifetime
- 2003-09-22 AU AU2003275075A patent/AU2003275075A1/en not_active Abandoned
- 2003-09-22 JP JP2004538315A patent/JP4614222B2/ja not_active Expired - Lifetime
- 2003-09-22 WO PCT/US2003/029653 patent/WO2004026328A1/en not_active Ceased
- 2003-09-22 EP EP10182239.3A patent/EP2311479B1/de not_active Expired - Lifetime
- 2003-09-22 SI SI200332088T patent/SI1549333T1/sl unknown
- 2003-09-22 AT AT03759343T patent/ATE525082T1/de active
- 2003-09-22 EP EP10182327.6A patent/EP2311480B1/de not_active Expired - Lifetime
- 2003-09-22 CA CA2502690A patent/CA2502690C/en not_active Expired - Lifetime
- 2003-09-22 US US10/528,496 patent/US7989589B2/en active Active
2010
- 2010-07-29 JP JP2010171021A patent/JP2010280688A/ja active Pending
2011
- 2011-07-06 US US13/177,140 patent/US8883413B2/en not_active Expired - Lifetime
- 2011-12-20 CY CY20111101259T patent/CY1112198T1/el unknown
2013
- 2013-02-06 JP JP2013021599A patent/JP5860573B2/ja not_active Expired - Lifetime
2014
- 2014-10-22 US US14/521,075 patent/US20170190741A9/en not_active Abandoned
2017
- 2017-07-06 US US15/643,069 patent/US20180118785A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7989589B2 (en)	2011-08-02
PT1549333E (pt)	2012-01-03
JP2013138673A (ja)	2013-07-18
HK1156862A1 (en)	2012-06-22
US8883413B2 (en)	2014-11-11
EP2311479B1 (de)	2014-07-23
JP2006505254A (ja)	2006-02-16
EP2311480A1 (de)	2011-04-20
JP4614222B2 (ja)	2011-01-19
CA2833202C (en)	2017-08-01
EP1549333B1 (de)	2011-09-21
CA2502690A1 (en)	2004-04-01
CY1112198T1 (el)	2015-12-09
EP2311479A1 (de)	2011-04-20
AU2003275075A1 (en)	2004-04-08
US20170190741A9 (en)	2017-07-06
JP5860573B2 (ja)	2016-02-16
US20110275150A1 (en)	2011-11-10
EP1549333A1 (de)	2005-07-06
US20100222550A1 (en)	2010-09-02
CA2833202A1 (en)	2004-04-01
CA2502690C (en)	2014-01-28
HK1156860A1 (en)	2012-06-22
US20180118785A1 (en)	2018-05-03
WO2004026328A1 (en)	2004-04-01
SI1549333T1 (sl)	2012-02-29
JP2010280688A (ja)	2010-12-16
EP1549333A4 (de)	2008-05-28
US20150158913A1 (en)	2015-06-11
EP2311480B1 (de)	2013-06-26
ES2373649T3 (es)	2012-02-07
DK1549333T3 (da)	2012-01-16

Legal Events

Date

Code

Title

Description

2012-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1549333

Country of ref document: EP

Publication	Publication Date	Title
ATE525082T1 (de)	2011-10-15	Compstatin-analoga mit verbesserter wirkung
WO2007062249A3 (en)	2007-09-13	Potent compstatin analogs
WO2004078777A3 (en)	2006-02-16	Dipeptidyl-peptidase protected proteins
DK1329458T5 (da)	2013-02-11	Peptider som sænker blodglucoseniveauer
ATE368688T1 (de)	2007-08-15	Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MXPA03002218A (es)	2004-03-18	Peptidos antimicrobianos y metodos de uso.
ATE551048T1 (de)	2012-04-15	Proteinhydrolysate enthaltende kosmetische zusammensetzungen
ATE278710T1 (de)	2004-10-15	Antimikrobiell wirksame peptide
ATE443076T1 (de)	2009-10-15	Von protease typ ii spaltbares peptid
EP1735335A4 (de)	2007-12-12	Zellabtötende peptide
ATE362487T1 (de)	2007-06-15	N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
BR9711540A (pt)	2001-06-19	Inibidores de protease proteìnico estabilizados e variantes dos mesmos
ATE445634T1 (de)	2009-10-15	Antimikrobielle peptide
ATE550345T1 (de)	2012-04-15	Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ATE336501T1 (de)	2006-09-15	Chi-conotoxinpeptide als inhibitoren neuronaler amintransporter
ATE449107T1 (de)	2009-12-15	Aus fisch gewonnene peptide und nukleinsäuren der cathelicidin familie und deren verwendung
ATE375360T1 (de)	2007-10-15	Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
ATE419271T1 (de)	2009-01-15	Antimikrobielle peptide
DE50013400D1 (de)	2006-10-12	Dna-sequenz und rekombinante herstellung eines graminaen-allergens
WO2006075253A3 (en)	2006-11-30	Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
FI20050753A0 (fi)	2005-07-14	Uudet peptidit
DE60008749D1 (de)	2004-04-08	Therapeutische peptide aus untersequenzen von bpi
SE0101519D0 (sv)	2001-04-27	Nucleic ACID
FI20040655A0 (fi)	2004-05-10	Proteiini- ja peptidistabilointi
DE50310131D1 (de)	2008-08-21	Peptide mit hohem cysteingehalt